EVA Group entered a successful strategic partnership with Eli Lilly and Company, a global healthcare leader and significant contributor to the healthcare industry in the Egyptian market.
Under this partnership, EVA Group will be holding the rights to sell, market, and distribute Lilly’s products, mainly in the areas of Oncology, Diabetes, Central Nervous System (CNS), Musculoskeletal, Urology and Autoimmune diseases. This partnership aims to increase healthcare professionals’ engagements and expand access to medicines to patients in Egypt who need them.
Riad Armanious, EVA Group Managing Director said: “The partnership between EVA Group and Lilly is a great milestone for both companies as well as Healthcare Providers and patients who need Lilly’s innovative therapies. At EVA we are looking forward to leveraging our capabilities and expertise around Egypt to bring Lilly’s innovative products to patients who need them. We are proud to be partnering with a Global Healthcare leader such as Lilly, and we will continue to expand our portfolio of products in both Egypt and international markets to advance treatment options for patients. This partnership today comes as a continuation of the multiple successes achieved by EVA in providing the latest medications in Egypt and around 40 countries around the world, including medicines for various chronic diseases.” In regards of distribution, Co-Managing Director of EVA Group, Linda Armanious, added: “With our in-depth knowledge of the local market and commercialization capabilities, we will expand the access of innovative healthcare in Egypt.”
Ahmed Fahmy, General Manager for Lilly North East Africa, added “For over 140 years, Lilly has been committed to our promise of uniting caring with discovery to make life better for people around the world. Through our partnership with EVA Group, Lilly’s products will continue to be present in Egypt, fulfilling our promise and ensuring that our medicines are accessible to more patients in Egypt who need them.”